Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Debt (2016 - 2025)

Haemonetics (HAE) has 16 years of Non-Current Debt data on record, last reported at $920.0 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 24.58% year-over-year to $920.0 million; the TTM value through Dec 2025 reached $920.0 million, down 24.58%, while the annual FY2025 figure was $921.2 million, 15.51% up from the prior year.
  • Non-Current Debt reached $920.0 million in Q4 2025 per HAE's latest filing, roughly flat from $920.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $1.2 billion in Q4 2024 and bottomed at $559.4 million in Q2 2022.
  • Average Non-Current Debt over 5 years is $843.8 million, with a median of $765.2 million recorded in 2021.
  • Peak YoY movement for Non-Current Debt: surged 158.46% in 2021, then dropped 24.58% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $698.0 million in 2021, then rose by 8.42% to $756.8 million in 2022, then increased by 13.22% to $856.8 million in 2023, then skyrocketed by 42.35% to $1.2 billion in 2024, then decreased by 24.58% to $920.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $920.0 million in Q4 2025, $920.4 million in Q3 2025, and $920.8 million in Q2 2025.